These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 17234518

  • 1. Vascular remodeling 1 year after cardiac transplantation.
    Li H, Tanaka K, Chhabra A, Oeser B, Kobashigawa JA, Tobis JM.
    J Heart Lung Transplant; 2007 Jan; 26(1):56-62. PubMed ID: 17234518
    [Abstract] [Full Text] [Related]

  • 2. Compensatory enlargement in transplant coronary artery disease: an intravascular ultrasound study.
    Li HY, Tanaka K, Oeser B, Wertman B, Kobashigawa JA, Tobis JM.
    Chin Med J (Engl); 2006 Apr 05; 119(7):564-9. PubMed ID: 16620697
    [Abstract] [Full Text] [Related]

  • 3. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia.
    Pethig K, Heublein B, Wahlers T, Dannenberg O, Oppelt P, Haverich A.
    J Heart Lung Transplant; 2004 Jan 05; 23(1):61-6. PubMed ID: 14734128
    [Abstract] [Full Text] [Related]

  • 4. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.
    Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R, Alderman E, Valantine H, Dureau G, Mancini D, Mamelok R, Gordon R, Wang W, Mehra M, Constanzo MR, Hummel M, Johnson J, Mycophenolate Mofetil Cardiac Study Investigators.
    J Heart Lung Transplant; 2005 May 05; 24(5):517-25. PubMed ID: 15896747
    [Abstract] [Full Text] [Related]

  • 5. Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: a multicenter prospective intravascular ultrasound study.
    Wong C, Ganz P, Miller L, Kobashigawa J, Schwarzkopf A, Valantine von Kaeper H, Wilensky R, Ventura H, Yeung AC.
    J Heart Lung Transplant; 2001 Apr 05; 20(4):385-92. PubMed ID: 11295575
    [Abstract] [Full Text] [Related]

  • 6. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L.
    Transplantation; 2011 Jul 27; 92(2):235-43. PubMed ID: 21677600
    [Abstract] [Full Text] [Related]

  • 7. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group.
    N Engl J Med; 2003 Aug 28; 349(9):847-58. PubMed ID: 12944570
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial.
    Kobashigawa JA, Tobis JM, Mentzer RM, Valantine HA, Bourge RC, Mehra MR, Smart FW, Miller LW, Tanaka K, Li H, Gjertson DW, Gordon RD.
    Am J Transplant; 2006 May 28; 6(5 Pt 1):993-7. PubMed ID: 16611335
    [Abstract] [Full Text] [Related]

  • 9. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 28; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 10. Optical coherence tomography and intravascular ultrasound evaluation of cardiac allograft vasculopathy with and without intimal neovascularization.
    Ichibori Y, Ohtani T, Nakatani D, Tachibana K, Yamaguchi O, Toda K, Akasaka T, Fukushima N, Sawa Y, Komuro I, Kotani J, Sakata Y.
    Eur Heart J Cardiovasc Imaging; 2016 Jan 28; 17(1):51-8. PubMed ID: 25976347
    [Abstract] [Full Text] [Related]

  • 11. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression.
    Petrakopoulou P, Anthopoulou L, Muscholl M, Klauss V, von Scheidt W, Uberfuhr P, Meiser BM, Reichart B, Weis M.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1622-9. PubMed ID: 16631000
    [Abstract] [Full Text] [Related]

  • 12. Vascular remodelling after cardiac transplantation: a 3-year serial intravascular ultrasound study.
    Li H, Tanaka K, Oeser B, Kobashigawa JA, Tobis JM.
    Eur Heart J; 2006 Jul 18; 27(14):1671-7. PubMed ID: 16790471
    [Abstract] [Full Text] [Related]

  • 13. Role of compensatory enlargement and shrinkage in transplant coronary artery disease. Serial intravascular ultrasound study.
    Lim TT, Liang DH, Botas J, Schroeder JS, Oesterle SN, Yeung AC.
    Circulation; 1997 Feb 18; 95(4):855-9. PubMed ID: 9054742
    [Abstract] [Full Text] [Related]

  • 14. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr 15; 61(7):1029-37. PubMed ID: 8623181
    [Abstract] [Full Text] [Related]

  • 15. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H.
    Nephrol Dial Transplant; 2006 Jul 15; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [Abstract] [Full Text] [Related]

  • 16. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
    Valantine H.
    J Heart Lung Transplant; 2005 Apr 15; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
    [Abstract] [Full Text] [Related]

  • 17. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study.
    Mehra MR, Ventura HO, Chambers R, Collins TJ, Ramee SR, Kates MA, Smart FW, Stapleton DD.
    J Am Coll Cardiol; 1995 Nov 15; 26(6):1537-44. PubMed ID: 7594082
    [Abstract] [Full Text] [Related]

  • 18. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus.
    Potena L, Fearon WF, Sydow K, Holweg C, Luikart H, Chin C, Weisshaar D, Mocarski ES, Lewis DB, Valantine HA, Cooke JP.
    Transplantation; 2008 Mar 27; 85(6):827-33. PubMed ID: 18360263
    [Abstract] [Full Text] [Related]

  • 19. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation.
    Merion RM, Henry ML, Melzer JS, Sollinger HW, Sutherland DE, Taylor RJ.
    Transplantation; 2000 Jul 15; 70(1):105-11. PubMed ID: 10919583
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of luminal narrowing in cardiac allograft vasculopathy: inadequate vascular remodeling rather than intimal hyperplasia is the major predictor of coronary artery stenosis. Working Group on Cardiac Allograft Vasculopathy.
    Pethig K, Heublein B, Wahlers T, Haverich A.
    Am Heart J; 1998 Apr 15; 135(4):628-33. PubMed ID: 9539478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.